# LUPIN (LUPIN) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/lupin

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹2,075
- Change: -1.10%
- As of: 2026-09-18
- 1D return: -0.72%
- 5D return: +0.25%
- 1M return: -5.38%
- Latest complete quarter: fy27_q1

## Faxioms Analysis

_As of 2026-09-18_

### Technical Outlook

As of September 18, 2026, LUPIN's technical stance is primarily bearish across daily and weekly timeframes, with a conflicting bullish signal on the monthly chart. Daily indicators show the price below key moving averages including the 20-day Exponential Moving Average (EMA) at ₹2134.55 and the 50-day Simple Moving Average (SMA) at ₹2278.87, alongside a bearish Supertrend reading at ₹2174.87. This is reinforced by the weekly timeframe, where the price is also below its 20-day EMA (₹2250.83) and 50-day EMA (₹2227.01), with a bearish Supertrend at ₹2367.44. However, the monthly view presents a bullish Supertrend at ₹1806.93, indicating potential underlying strength despite shorter-term weakness. The stock is currently trading near its nearest support level of ₹2080.83, approximately 0.1% below the current price of ₹2083.0. Nearest resistance is observed at ₹2115.37, about 1.55% higher. The stock has experienced an unusual upward price move of 3% on September 17, 2026, with extreme severity. Current risk factors include an annualized volatility of 24% and a maximum drawdown of -23%.

- Daily and weekly timeframes indicate a bearish trend, with price below key moving averages and Supertrend.
- Monthly timeframe shows a bullish Supertrend, suggesting potential conflicting signals.
- Nearest support is at ₹2080.83, with resistance at ₹2115.37.
- An unusual upward price move with extreme severity occurred on September 17, 2026.
- Watch for a break below ₹2080.83 to confirm further downside, or a sustained move above ₹2115.37 to challenge the bearish short-term outlook.

- Harami
- Morning Star
- Bearish Engulfing Reversal
- Bullish Engulfing Reversal
- Outside Bar

### News Context

Lupin shares saw a modest increase of over 1% on September 17, 2026, following Nomura's reaffirmation of a 'Buy' rating with a target price of ₹2,675. This positive analyst sentiment comes amidst a broader market context where the pharmaceutical sector's shares were snapping a five-day losing streak, though overall market sentiment remained cautious due to potential US interest rate hikes. The domestic pharmaceutical market, as of August, showed sustained growth driven by price increases and new product introductions, but concerns about weak volumes and US tariff uncertainty continue to impact margin recovery, a key factor for sector performance.

- On September 17, 2026, Lupin shares gained over 1% after Nomura reiterated a 'Buy' rating and a target price of ₹2,675.
- The pharmaceutical sector experienced a positive trading day on September 17, 2026, ending a five-day decline.
- Domestic pharmaceutical market growth in August was supported by price hikes and new launches, according to a September 16, 2026 report.
- Concerns regarding weak volumes and US tariff uncertainty remain a factor for sustained margin recovery in the pharma sector.
- A September 12, 2026 query discussed the stock outlook for Lupin among other companies.

- Sensex, Nifty trade in positive terrain; pharma shares snap 5-day losing streak
- Can an eye drop replace reading glasses for 8 hours? Can it create a new drug market?
- Lupin shares gain over 1 % after Nomura reaffirms 'Buy', Rs 2,675 target
- Domestic pharma market sustains growth momentum, but margins remain key
- Tech Query: Lupin, KFin Technologies, KPI Green Energy, Goodluck India - What is the outlook? Where are these stocks headed?

### What Changed

As of September 18, 2026, Lupin's stock price was ₹2083.0, a decrease from its previous price of ₹2098.1. The available evidence does not indicate any new filings or news developments for the company. The daily and weekly trends are not specified in the recent data. The company's common name remains Lupin, and it is listed on the NSE.

- Lupin's stock price on September 18, 2026, was ₹2083.0.
- The stock price on the preceding observation date was ₹2098.1.
- No new filings or news were reported for Lupin as of September 18, 2026.

### Official Filings

Lupin Limited has disclosed several key developments. On August 17, 2026, the company announced U.S. FDA approval for its Pitolisant Tablets. Subsequently, on September 4, 2026, Lupin received U.S. FDA approval for its ANDA for Modafinil Tablets USP, 100 mg and 200 mg. These tablets are indicated for excessive sleepiness and are bioequivalent to Provigil Tablets, which had estimated annual U.S. sales of USD 70.7 million as of July 2026. In a strategic move, on August 20, 2026, Lupin's subsidiary VISUfarma B.V. entered an exclusive license agreement with Visus Therapeutics, Inc. to commercialize YUVEZZITM, a Presbyopia treatment, in the European Union, UK, Switzerland, Norway, and Iceland. This agreement includes a €20 million strategic investment and potential milestone payments up to €55 million, plus royalties. The company also reported the allotment of 30,967 equity shares on August 25, 2026, under its ESOP/ESPS scheme, which increased the issued and paid-up share capital. Separately, Lupin informed the market about the passing of Dr. Sofia Mumtaz, President, Legal & Compliance, Canada, ANZ & NEA Business, on August 17, 2026. Looking ahead, Lupin is scheduled to participate in the Kotak Healthcare Conference on September 17, 2026, and the J.P. Morgan India Conference on September 21, 2026.

- On August 17, 2026, Lupin received U.S. FDA approval for Pitolisant Tablets.
- On September 4, 2026, Lupin received U.S. FDA approval for Modafinil Tablets USP (100 mg and 200 mg), bioequivalent to Provigil Tablets with estimated annual U.S. sales of USD 70.7 million (IQVIA MAT Jul 2026).
- On August 20, 2026, a subsidiary entered an exclusive license agreement for YUVEZZITM (Presbyopia treatment) in the EU and UK, involving a €20 million investment and up to €55 million in milestone payments, plus royalties.
- On August 25, 2026, 30,967 equity shares were allotted under an ESOP/ESPS scheme, increasing the company's issued and paid-up share capital.
- Lupin will participate in the Kotak Healthcare Conference on September 17, 2026, and the J.P. Morgan India Conference on September 21, 2026.

- Lupin Limited has informed the Exchange about Schedule of Institutional Investors Meets. |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Lupin Limited has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- Lupin Limited has informed the Exchange regarding a press release dated September 04, 2026, titled "Lupin Receives U.S. FDA Approval for Modafinil Tablets, USP". |SUBJECT: Press Release
- Lupin Limited has informed the Exchange regarding Allotment of 30967 Shares. |SUBJECT: ESOP/ESOS/ESPS
- LUPIN LIMITED has informed the Exchange regarding Allotment of Securities |SUBJECT: Alteration Of Capital and Fund Raising-XBRL
- Lupin Limited has informed the Exchange about VISUfarma B.V., the Netherlands, a wholly owned subsidiary of the Company, has entered into an Exclusive License Agreement with Visus Therapeutics, Inc. U.S.A. |SUBJECT: Arrangements for strategic, technical, manufacturing, or marketing tie up
- Lupin Limited has informed the Exchange about Arrangements (Sub-para 2-Para B) |SUBJECT: Arrangements (Sub-para 2-Para B)
- Lupin Limited has informed the Exchange regarding Demise of Dr. Sofia Mumtaz, President, Legal & Compliance, Canada, ANZ & NEA Business, a Senior Management Personnel of the Company. |SUBJECT: Demise
- Lupin Limited has informed the Exchange about Change in Directors/KMP/SMP/Auditor/RTA |SUBJECT: Change in Directors/KMP/SMP/Auditor/RTA
- Lupin Limited has informed the Exchange regarding a press release dated August 17, 2026, titled "Lupin Announces Approval from U.S. FDA for Pitolisant Tablets". |SUBJECT: Press Release

### Fundamentals

Lupin's reported results show a recent upward trend in revenue from operations, reaching ₹8,276.89 crore in Q1 FY2026-27. This growth was accompanied by an increase in expenses, which rose to ₹6,389.83 crore in the same period. Profit Before Tax (PBT) saw an increase to ₹2,017.38 crore in Q1 FY2026-27. However, Profit After Tax (PAT) experienced a slight decrease to ₹1,416.98 crore in Q1 FY2026-27, down from ₹1,468.67 crore in Q4 FY2025-26, despite the rise in PBT. Finance costs remained relatively stable, while tax expenses increased significantly in Q1 FY2026-27 to ₹600.38 crore.

- Revenue from operations increased sequentially from ₹7,167.52 crore in Q3 FY2025-26 to ₹8,276.89 crore in Q1 FY2026-27.
- Expenses also rose sequentially, from ₹5,333.61 crore in Q3 FY2025-26 to ₹6,389.83 crore in Q1 FY2026-27.
- Profit Before Tax (PBT) grew to ₹2,017.38 crore in Q1 FY2026-27.
- Profit After Tax (PAT) was ₹1,416.98 crore in Q1 FY2026-27, a decrease from ₹1,468.67 crore in Q4 FY2025-26.
- Tax expense for Q1 FY2026-27 was ₹600.38 crore, an increase from ₹459.33 crore in Q4 FY2025-26.

### Bull Case

The domestic pharmaceutical market is showing sustained growth, driven by price increases and new product introductions, according to recent sector commentary. While this indicates a positive environment for pharmaceutical companies operating within India, the overall performance and margin recovery remain key factors to monitor. An external analyst from Nomura has maintained a 'Buy' rating on Lupin with a target price of ₹2,675, suggesting a constructive outlook from their perspective.

- The domestic pharma market sustained growth in August, supported by price hikes and new launches.
- Nomura has reaffirmed a 'Buy' rating on Lupin with a target price of ₹2,675.

- Sensex, Nifty trade in positive terrain; pharma shares snap 5-day losing streak
- Can an eye drop replace reading glasses for 8 hours? Can it create a new drug market?
- Lupin shares gain over 1 % after Nomura reaffirms 'Buy', Rs 2,675 target
- Domestic pharma market sustains growth momentum, but margins remain key
- Tech Query: Lupin, KFin Technologies, KPI Green Energy, Goodluck India - What is the outlook? Where are these stocks headed?

### Bear Case

The company's stock is exhibiting a bearish trend on the daily chart, with the Super Trend indicator suggesting a downward movement. Technical indicators like the 20-day Exponential Moving Average (EMA) at ₹2,134.55 and the 50-day Simple Moving Average (SMA) at ₹2,278.87 are positioned above the current closing price of ₹2,083.0, indicating potential resistance. Recent returns show a decline across various periods, including a -6% return over the last month and a -10% return over the last three months. The stock has also experienced a current drawdown of -17% and a maximum drawdown of -23%, suggesting significant price volatility and potential for further declines. The domestic pharmaceutical market, while showing growth, faces challenges with weak volumes and uncertainty regarding US tariffs, which could impact sustained margin recovery.

- The daily Super Trend indicator is 'bearish' as of 2026-09-18.
- The stock has shown negative returns over multiple recent periods, including -6% in the last month and -10% in the last three months.
- The current drawdown stands at -17%, with a maximum drawdown of -23% observed.
- The domestic pharma market faces headwinds from weak volumes and US tariff uncertainty, potentially impacting margins.

- Sensex, Nifty trade in positive terrain; pharma shares snap 5-day losing streak
- Can an eye drop replace reading glasses for 8 hours? Can it create a new drug market?
- Lupin shares gain over 1 % after Nomura reaffirms 'Buy', Rs 2,675 target
- Domestic pharma market sustains growth momentum, but margins remain key
- Tech Query: Lupin, KFin Technologies, KPI Green Energy, Goodluck India - What is the outlook? Where are these stocks headed?

### FAQs

**What recent U.S. FDA approval did Lupin receive and what is its potential market size?**

On September 4, 2026, Lupin Limited announced it received U.S. FDA approval for its ANDA for Modafinil Tablets USP, in 100 mg and 200 mg strengths. These tablets are bioequivalent to Provigil Tablets by Nuvo Pharmaceuticals and are indicated for excessive sleepiness. The estimated annual U.S. sales for the reference listed drug were USD 70.7 million as of July 2026.

**What is the current technical trend for Lupin shares based on daily and weekly analysis?**

As of September 18, 2026, the daily trend for Lupin shares indicates a bearish SuperTrend direction with a value of 2174.87. The Exponential Moving Averages (EMA) and Simple Moving Averages (SMA) on a daily basis are below the current closing price of ₹2083.0, with negative slopes. On a weekly basis, the SuperTrend is also bearish at 2367.44, with the EMA and SMA values also above the current closing price and showing negative slopes, except for the weekly 50-period SMA which has a positive slope.

**What upcoming investor events has Lupin scheduled?**

Lupin Limited has informed the exchange that it will participate in two upcoming investor events. The company is scheduled to attend the Kotak Healthcare Conference on September 17, 2026, and the J.P. Morgan India Conference on September 21, 2026. Both events are planned as in-person group meetings.

**How have Lupin's share price returns performed over different periods?**

As of the latest available data, Lupin's period returns show a decline over several shorter terms. The return for the last month (1m) was -7%, for the last three months (3m) it was -10%, and for the last six months (6m) it was -10%. The year-to-date (YTD) return was -1%, and the return since the start of the data series was -12%. However, the return over the last year (1y) was positive at 2%.

- Sensex, Nifty trade in positive terrain; pharma shares snap 5-day losing streak
- Can an eye drop replace reading glasses for 8 hours? Can it create a new drug market?
- Lupin shares gain over 1 % after Nomura reaffirms 'Buy', Rs 2,675 target
- Domestic pharma market sustains growth momentum, but margins remain key
- Tech Query: Lupin, KFin Technologies, KPI Green Energy, Goodluck India - What is the outlook? Where are these stocks headed?
- Lupin Limited has informed the Exchange about Schedule of Institutional Investors Meets. |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Lupin Limited has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- Lupin Limited has informed the Exchange regarding a press release dated September 04, 2026, titled "Lupin Receives U.S. FDA Approval for Modafinil Tablets, USP". |SUBJECT: Press Release
- Lupin Limited has informed the Exchange regarding Allotment of 30967 Shares. |SUBJECT: ESOP/ESOS/ESPS
- LUPIN LIMITED has informed the Exchange regarding Allotment of Securities |SUBJECT: Alteration Of Capital and Fund Raising-XBRL
## Technical analytics

- As of: 2026-09-18
- Daily trend: Moderate Downtrend
- Weekly trend: Weak Downtrend
- Pivot point: ₹2,080.83
- Risk regime: Price Risk Requires Attention

### Support levels
- 2071.77294921875
- 1982.176513671875
- 1916.240625

### Resistance levels
- 2126.3218749999996
- 2161.7749999999996
- 2238.6734863281254

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | -0.72% |
| return_10 | -2.30% |
| return_1m | -6.68% |
| return_1y | +1.78% |
| return_20 | -5.38% |
| return_3m | -10.49% |
| return_5 | +0.25% |
| return_6m | -9.53% |
| return_since_start | -11.92% |
| return_ytd | -0.94% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | elevated_risk |
| label | Price risk requires attention |
| summary | Recent drawdown or price variability is high enough to warrant closer monitoring. |
| maximum_drawdown | -22.72% |
| annualized_volatility | +24.02% |

## Quarterly financials

- Latest complete quarter: fy27_q1

# Revenue Reaches New High, but Tax Spike Leads to Sequential Net Profit Decline

Lupin reported its highest quarterly revenue, rising 10.7% sequentially to ₹8,276.89 crore. However, expenses grew faster, and a sharp increase in tax expense caused net profit to decline 3.5% from the prior quarter. Year-over-year, both revenue and profit before tax grew over 30%, but net profit growth was limited to 16% as the tax bill more than tripled.

## Revenue Growth Accelerates
Revenue from operations increased 10.73% sequentially (₹802 crore) and 32.04% year-over-year (₹2,009 crore). This is the fourth consecutive quarterly increase, with the sequential pace accelerating from 4.3% in Q4 FY2025-26. The absolute sequential gain is the largest in recent quarters.

## Expenses Rise Faster Than Revenue
Total expenses grew 15.01% sequentially, outpacing the 10.73% revenue growth. The expense-to-revenue ratio rose from 74.3% in Q4 to 77.2% in Q1. Year-over-year, expenses grew 29.56%, slightly below revenue growth of 32.04%, so the expense ratio improved to 77.2% from 78.7% a year ago.

## Profit Before Tax Growth Moderates
Profit before tax increased 4.64% sequentially to ₹2,017.38 crore, a slower pace than revenue due to the faster expense growth. Year-over-year, PBT grew 42.52%, outpacing revenue growth, reflecting improved profitability compared with the same quarter last year.

## Tax Expense Surge Drives Net Profit Decline
Tax expense jumped 30.71% sequentially to ₹600.38 crore, the highest among the reported quarters. The effective tax rate (tax expense divided by PBT) rose from 23.8% in Q4 to 29.8% in Q1. Year-over-year, tax expense more than tripled (up 209.35% from ₹194.08 crore), while PBT grew 42.5%. As a result, net profit fell 3.52% sequentially to ₹1,416.98 crore, despite higher PBT. Year-over-year, net profit grew 16.01%, well below PBT growth.

## Finance Costs Edge Lower
Finance costs decreased 8.75% sequentially to ₹109.64 crore, reversing the upward trend of the previous three quarters. Year-over-year, finance costs were 19.49% higher.

## Comprehensive Income and Earnings Per Share
Comprehensive income decreased 5.25% sequentially to ₹1,452.49 crore, a slightly larger decline than net profit, suggesting other comprehensive losses during the quarter. Basic earnings per share fell from ₹31.96 to ₹30.95 sequentially, but rose 15.92% year-over-year to ₹30.95.

## Key Takeaway
Lupin delivered its highest quarterly revenue in the period under review, with year-over-year revenue growth of 32% and PBT growth of 42.5%. However, net profit declined sequentially as expenses grew faster than revenue and tax expense rose sharply. The effective tax rate increased significantly from both the prior quarter and the same quarter last year, limiting the translation of revenue growth into net profit.

### Ratios

## Official filings

- 2026-09-08 — Generic Announcement: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Lupin2_08092026163044_SE_Intimation_Schedule_of_Analyst_Investors_Meet.pdf)
- 2026-09-08 — Generic Announcement: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1988_WebXMLFile_20260908_164140317.xml)
- 2026-09-04 — Press Release: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Lupin2_04092026173742_SELetterPressRelease.pdf)
- 2026-08-25 — Generic Announcement: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Lupin2_25082026172557_BSENSE25082026_signed.pdf)
- 2026-08-25 — Generic Announcement: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/ALTERATION_OF_CAPITAL_AND_FUND_RAISING_1988_WebXMLFile_20260825_174931687.xml)
- 2026-08-20 — Generic Announcement: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Lupin2_20082026104309_SE_Intimation_20082026.pdf)
- 2026-08-20 — Generic Announcement: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/REG30_PARA_B_1988_WebXMLFile_20260820_110501067.xml)
- 2026-08-18 — Generic Announcement: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Lupin2_18082026220346_SELetter_Demise.pdf)
- 2026-08-18 — Generic Announcement: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_1988_WebXMLFile_20260818_221911160.xml)
- 2026-08-17 — Press Release: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Lupin2_17082026121641_SELetterPressRelease.pdf)
- 2026-08-13 — Generic Announcement: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1988_WebXMLFile_20260813_104359994.xml)
- 2026-08-12 — Generic Announcement: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Lupin2_12082026174715_SE_Letter_signed.pdf)
- 2026-08-10 — Generic Announcement: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Lupin2_10082026160841_SE_Intimation_Schedule_of_Analyst_Investors_Meet.pdf)
- 2026-08-10 — Generic Announcement: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1988_WebXMLFile_20260810_162244415.xml)
- 2026-08-08 — Generic Announcement: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Lupin2_08082026120925_SE_Intimation_for_Newspaper_publication.pdf)
- 2026-08-07 — Generic Announcement: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_1988_WebXMLFile_20260807_214124250.xml)
- 2026-08-07 — Generic Announcement: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Lupin2_07082026213313_SignedSE_Intimation_Audio_Link_Q1_FY27.pdf)
- 2026-08-06 — Earnings Presentation: Lupin Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/Lupin2_07082026011112_SE_Intimation_Investor_Presentation-07082026.pdf)
- 2026-08-06 — Generic Announcement: Lupin Limited's Board of Directors approved the unaudited financial results for the quarter ended June 30, 2026, on August 06, 2026. The company reported consolidated revenue of 82,768.9 million and a profit after tax of 14,169.8 million for the quarter. The company also disclosed the acquisition of VISUfarma B.V. for a consideration of 20,902.7 million and settlement of an antitrust matter for 2,654.1 million. — [Official attachment](https://nsearchives.nseindia.com/corporate/Lupin2_06082026215040_SE_Outcome_UFR_intimation.pdf)
- 2026-08-06 — Earnings Presentation: Lupin Limited reported its Q1 FY27 unaudited financial results, with sales reaching INR 82,172 million, a 33% year-over-year increase. EBITDA was INR 24,635 million, up 50% YoY, and Net Income was INR 14,150 million, up 16% YoY. The company also highlighted key developments including EMA approval for NaMuscla® in children and China approval for Oseltamivir Phosphate oral suspension. — [Official attachment](https://nsearchives.nseindia.com/corporate/Lupin2_06082026220851_SE_Intimation_Investor_Presentation.pdf)
- 2026-08-06 — Press Release: Lupin Limited reported its unaudited financial results for the quarter ended June 30, 2026, with total revenue from operations of INR 82,769 Mn, a 32.0% year-over-year increase. Profit After Tax (PAT) was INR 14,170 Mn, up 16.0% year-over-year. Sales in the U.S. increased by 42.9% to INR 34,348 Mn, and the company received 6 ANDA approvals from the U.S. FDA during the quarter. Investment in R&D for the quarter was INR 6,077 Mn. — [Official attachment](https://nsearchives.nseindia.com/corporate/Lupin2_06082026215741_SE_Intimation_Press_Release.pdf)
- 2026-08-04 — Generic Announcement: Lupin Limited held its Forty-Fourth Annual General Meeting on August 04, 2026, through video conferencing. All five resolutions presented, including the adoption of financial statements for the year ended March 31, 2026, the declaration of a final dividend of ₹18 per equity share, the appointment of Nilesh D. Gupta as Director, the appointment of Deloitte Haskins & Sells Chartered Accountants LLP as Statutory Auditors, and the ratification of the Cost Auditor's remuneration, were passed by the shareholders with the requisite majority. — [Official attachment](https://nsearchives.nseindia.com/corporate/Lupin2_04082026214655_SE_Intimation_for_Outcome_of_AGM.pdf)
- 2026-07-31 — Press Release: Lupin Limited announced on July 31, 2026, that it received U.S. FDA approval and launched its Sugammadex Injection in the United States. This product is bioequivalent to Bridion® Injection and is used for reversing neuromuscular blockade in surgical patients aged 2 and older. — [Official attachment](https://nsearchives.nseindia.com/corporate/Lupin2_31072026111234_SELetterPressRelease.pdf)
- 2026-07-31 — Press Release: Lupin Limited announced on July 31, 2026, that it received U.S. FDA approval for its Abbreviated New Drug Application for Diazepam Injection USP, 10 mg/2 mL (5 mg/mL), Single-Dose Prefilled Syringes. This product is bioequivalent to Valium® Injection and is indicated for anxiety disorders. The estimated annual sales for this product in the U.S. were USD 77.9 million as of May 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/Lupin2_31072026170502_SELetterPressRelease.pdf)
- 2026-07-22 — Official Filing: Lupin Limited will hold a board meeting on August 6, 2026, to approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The trading window will be closed from July 1, 2026, to August 8, 2026.

## News and market events

- 2026-09-17 — BUSINESS: **Sensex, Nifty trade in positive terrain; pharma shares snap 5-day losing streak** — The Feds indication of another rate hike in 2026 is likely to keep investors cautious, particularly in rate-sensitive and foreign-portfolio-investment-driven segments. However, buying interest in select domestic sectors provided some support, the Nifty hovered above the 23,250 mark. Market participants are likely to track currency movements, US bond yields and foreign fund flows for further direction. — [Source](https://www.business-standard.com/markets/capital-market-news/sensex-nifty-trade-in-positive-terrain-pharma-shares-snap-5-day-losing-streak-126091700646_1.html)
- 2026-09-17 — BUSINESSTODAY: **Can an eye drop replace reading glasses for 8 hours? Can it create a new drug market?** — Can an eye drop replace reading glasses for 8 hours? Can it create a new drug market? — [Source](https://www.businesstoday.in/latest/corporate/story/can-an-eye-drop-replace-reading-glasses-for-8-hours-can-it-create-a-new-drug-market-556114-2026-09-17)
- 2026-09-17 — MONEYCONTROL: **Lupin shares gain over 1 % after Nomura reaffirms 'Buy', Rs 2,675 target** — Lupin, Lupin news, Lupin stocks, Lupin shares, Nomura — [Source](https://www.moneycontrol.com/news/business/stocks/lupin-shares-gain-over-1-after-nomura-reaffirms-buy-rs-2-675-target-14031839.html)
- 2026-09-16 — Mint: **Domestic pharma market sustains growth momentum, but margins remain key** — Domestic pharma growth remained strong in August, led by price hikes and new launches, but weak volumes and US tariff uncertainty mean a sustained margin recovery will be crucial for sector performance. — [Source](https://www.livemint.com/market/mark-to-market/indian-pharma-market-ipm-pharma-stocks-domestic-pharma-dr-reddy-s-laboratories-sun-pharma-ajanta-pharma-glenmark-11789538290089.html)
- 2026-09-12 — The Hindu: **Tech Query: Lupin, KFin Technologies, KPI Green Energy, Goodluck India - What is the outlook? Where are these stocks headed?** — Explore the stock outlook for Lupin, KFin Technologies, KPI Green Energy, and Goodluck India, including investment strategies and potential risks. — [Source](https://www.thehindubusinessline.com/portfolio/technical-analysis/tech-query-lupin-kfin-technologies-kpi-green-energy-goodluck-india-what-is-the-outlook-where-are-these-stocks-headed/article71456356.ece)
- 2026-09-07 — CNBC-TV18: **These four stocks are in focus after order wins worth over ₹900 crore and drug approvals by USFDA** — Most of the stocks that will be reacting to their respective order wins / drug approvals have delivered negative to flat returns so far this year. — [Source](https://www.cnbctv18.com/market/these-four-stocks-are-in-focus-after-order-wins-worth-over-%25e2%2582%25b9900-crore-and-drug-approvals-by-usfda-19985156.htm)
- 2026-09-07 — MONEYCONTROL: **Lupin shares in focus post Modafinil tablets approval from USFDA** — Lupin,Lupin share price,Lupin share price live today — [Source](https://www.moneycontrol.com/news/business/markets/lupin-shares-in-focus-post-modafinil-tablets-approval-from-usfda-14023536.html)
- 2026-09-07 — BUSINESSTODAY: **Top stocks in news: JSW Steel, TMCV, Mazagon, RVNL, Lupin, Molbio, Purple Style, HEG, Lemon Tree** — Stocks in news, Stocks in buzz, Stocks to buy, Stocks to watch, JSW Steel, Tata Motors, TMCV, Mazagon Dock Engineering, RVNL, Rail Vikas Nigam, Lupin, Molbio Diagnostics, Purple Style Labs, HEG, Lemon Tree Hotels, Shiprocket, Behari Lal Engineering, Mazagon Dock Shipbuilders, Lemon Tree Hotels, Cohance Lifesciences, Urban Enviro Waste Management, Brigade Enterprises, Price Focus, Nava, Jayaswal Neco Industries — [Source](https://www.businesstoday.in/markets/stocks/story/top-stocks-in-news-jsw-steel-tmcv-mazagon-rvnl-lupin-molbio-purple-style-heg-lemon-tree-blel-553519-2026-09-07)
- 2026-09-07 — Economic Times: **Stocks in news: Tata Motors, RVNL, Eicher Motors, Mazagon Dock and Lupin** — Indian equity markets experienced volatility, with the Nifty 50 extending its losing streak for four weeks. Escalating US-Iran hostilities pushed crude oil prices higher, impacting overall market sentiment. Several companies, including Tata Motors and Rail Vikas Nigam, are expected to be active on Monday. Mazagon Dock Shipbuilders and Eicher Motors also reported significant corporate developments. Lupin received US FDA approval, while JSW Steel saw production increases in August. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/stocks-in-news-tata-motors-rvnl-eicher-motors-mazagon-dock-and-lupin/articleshow/133844968.cms)
- 2026-09-06 — Mint: **Top stocks in focus on Monday: Why investors watch RVNL, Mazagon Dock, Tata Motors shares - Know news, triggers** — Rail Vikas Nigam (RVNL), Lupin, Tata Motors, Mazagon Dock Shipbuilders, JSW Steel, Lupin among the stocks likely to remain in focus. — [Source](https://www.livemint.com/market/stock-market-news/top-stocks-in-focus-on-monday-why-investors-watch-rvnl-mazagon-dock-tata-motors-shares-know-news-triggers-11788692544285.html)
- 2026-09-06 — CNBC-TV18: **Stocks to Watch for September 7: RVNL, Mazagon Dock, Tata Motors, JSW Steel and more** — From RVNL receiving a ₹903 crore Letter of Award from SJVN Thermal to Lupin securing US FDA approval for Modafinil Tablets USP, 100 mg and 200 mg, here are the stocks to track ahead of Monday’s trading session. — [Source](https://www.cnbctv18.com/photos/market/stocks-to-watch-for-september-7-rvnl-mazagon-dock-tata-motors-jsw-steel-and-more-19984660.htm)
- 2026-08-27 — MONEYCONTROL: **Price Action | Lupin shares slip as Citi downgrades to sell; ICICI Pru AMC slips 3% on block deal** — Buzzing Stocks — [Source](https://www.moneycontrol.com/news/business/markets/price-action-lupin-shares-slip-as-citi-downgrades-to-sell-icici-pru-amc-slips-3-on-block-deal-14016249.html)
- 2026-08-27 — CNBC-TV18: **Lupin share price: Citi downgrades, cuts target; Bernstein sees Kalydeco ruling as key positive** — Citi has downgraded Lupin to 'Sell' and cut its price target to ₹2,050, citing weakness in the US base business and limited pipeline visibility, while Bernstein remains bullish following the company’s favourable Kalydeco patent ruling. — [Source](https://www.cnbctv18.com/market/lupin-share-price-citi-downgrades-cuts-target-bernstein-sees-kalydeco-ruling-as-key-positive-19977992.htm)
- 2026-08-27 — Mint: **Stocks to buy for short term: Amol Athawale of Kotak Securities bullish on 3 stocks; do you own any?** — Amol Athawale from Kotak Securities highlights three stocks poised for growth in the coming weeks amidst a fluctuating market. With pivotal resistance levels identified, traders have potential opportunities for profit.  — [Source](https://www.livemint.com/market/stock-market-news/stocks-to-buy-for-short-term-amol-athawale-of-kotak-securities-bullish-on-3-stocks-do-you-own-any-11787754452058.html)
- 2026-08-18 — Mint: **Stocks to watch: Paytm, Bharti Airtel, Netweb Technologies among shares in focus today; check list here** — Stock market today: Gift Nifty was trading near the 24,320 mark, down over 72.70 points from the previous close of Nifty futures. — [Source](https://www.livemint.com/market/stock-market-news/stocks-to-watch-paytm-bharti-airtel-netweb-technologies-among-shares-in-focus-today-check-list-here-11787018700385.html)
- 2026-08-18 — Economic Times: **Stocks in news: Airtel, Paytm, SpiceJet, ONGC and ZEE** — Markets extended their losing streak for a fifth consecutive session on Monday. Airtel Payments Bank appointed Shabnam Sinha as its new chairperson. Paytm's parent company will see a significant share sale on Tuesday. SpiceJet's bankruptcy petitions were deferred after a settlement was reached. ONGC secured a US license to resume operations in Venezuela. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/stocks-in-news-airtel-paytm-spicejet-ongc-and-zee/articleshow/133303467.cms)
- 2026-08-17 — The Hindu: **Lupin gets U.S FDA nod for Pitolisant tablets** — Lupin receives U.S. FDA approval for Pitolisant tablets, a generic treatment for excessive daytime sleepiness and cataplexy. — [Source](https://www.thehindu.com/business/industry/lupin-gets-us-fda-nod-for-pitolisant-tablets/article71357220.ece)
- 2026-08-17 — CNBC-TV18: **Sensex Today | Stock Market LIVE Updates: Nifty IT index down 500 points; HCLTech, Infosys top losers** — Stock Market Live Updates: We are in the second half of the day's trade, and the markets have managed a remarkable recovery from the lows. The Nifty has recovered over 130 points from lows, moving above the 24,350 mark. The Nifty Bank has turned green, jumping by over 150 points. Hindalco, HDFC Life and Bajaj Fin are the top gainers. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-reliance-hdfc-bank-cochin-nmdc-voltas-gmr-jupiter-share-price-liveblog-19970547.htm)
- 2026-08-17 — The Hindu: **Sensex today | Stock Market LIVE: Sensex off day's low; down 200 points, Nifty holds 24,300; Voltas shares fall 6%** — Sensex, Nifty, Share Prices Live updates: At 12:00 pm, Sensex dropped 407.68 points or 0.52% to 77,601.57, Nifty slipped 94.90 points (-0.39%) to 24,271.10 — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-live-updates-17th-august-2026/article71354693.ece)
- 2026-08-11 — The Hindu: **Stocks to Watch, Aug 11: BSE, Wipro, TCS, HCLTech, BEL, Lupin & 20+ stocks** — From BSE’s entry into the Nifty 50 and Wipro’s exit to fresh orders, business expansions and regulatory approvals, a packed corporate news flow could keep more than two dozen stocks in focus on Tuesday. — [Source](https://www.thehindubusinessline.com/markets/buzzing-stocks-bse-wipro-tcs-hcltech-bel-lupin-and-20-stocks-in-focus-on-tuesday/article71330849.ece)
- 2026-08-11 — The Hindu: **Tamil Nadu-based Milky Mist IPO opens today: Why SBI Securities, Anand Rathi recommend ‘Subscribe’** — The IPO opens at a price band of ₹133-140 a share, after the company raised ₹465 crore from anchor investors ahead of the issue — [Source](https://www.thehindubusinessline.com/markets/tamil-nadu-based-milky-mist-ipo-opens-today-why-sbi-securities-anand-rathi-recommend-subscribe/article71330871.ece)
- 2026-08-10 — CNBC-TV18: **Lupin wins US FDA nod for sodium zirconium cyclosilicate to treat hyperkalemia** — Shares of Lupin Ltd ended at ₹2,275.00, down by ₹85.00, or 3.60%, on the BSE. — [Source](https://www.cnbctv18.com/market/stocks/lupin-share-price-wins-us-fda-nod-for-sodium-zirconium-cyclosilicate-to-treat-hyperkalemia-19965895.htm)
- 2026-08-10 — CNBC-TV18: **Stocks to Watch for August 11: Vodafone Idea, Bharat Electronics, Lloyds Metals, Bosch and more** — From BEL securing additional orders worth ₹541 crore to Lloyds Metals & Energy, KEC International, Vodafone Idea and others reporting their June-quarter results after market hours, these are the stocks likely to remain in focus ahead of Tuesday’s trading session. Ashiana Housing, Allcargo Terminals, Kalyani Forge also are also due to report results on August 11. — [Source](https://www.cnbctv18.com/photos/market/stocks-to-watch-for-august-11-vodafone-idea-bharat-electronics-lloyds-metals-bosch-and-more-19965863.htm)
- 2026-08-10 — CNBC-TV18: **Sensex Today | Stock Market LIVE Updates: Nifty rises towards 24,600; Hitachi Energy up 10%** — Sensex Today | Stock Market LIVE Updates: The markets are trading in a volatile space, as the Nifty index remains cautious with negative bias. The index is looking to hold onto the 24,500 mark. The Nifty Bank is also under pressure, down 200 points. SBI, Adani Ports and HDFC Life are the top laggards. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-oil-banks-midcaps-bajaj-fin-pfc-kaynes-ola-bharat-forge-share-price-liveblog-19965161.htm)
- 2026-08-10 — CNBC-TV18: **Q1 Results LIVE Updates: Hitachi Energy shares rise 8%; Bharat Forge, Vodafone Idea report today** — Q1 Results LIVE Updates: Bharat Forge Vodafone Idea, Hindustan Copper, Wockhardt, Info Edge, Zee Entertainment, Linde India, ideaForge, Gland Pharma, Bosch, Astra Micro, AstraZeneca Pharma, are among the companies reporting their earnings today. Earnings reactions will come from stocks like Kaynes Tech, PFC, Delhivery and many other stocks. Watch this space for all the LIVE results updates of the first quarter. — [Source](https://www.cnbctv18.com/market/q1-results-live-updates-today-vodafone-idea-bharat-forge-pfc-kaynes-sbi-oil-titan-wockhardt-hind-copper-delhivery-ola-share-price-liveblog-19965183.htm)

## Business profile

**Strategic vision:** Develops and delivers pharmaceutical solutions globally.

### Business segments
- **Global Generics:** Focuses on providing accessible and affordable generic medicines across developed markets, with a significant presence in the U.S.
- **Emerging Markets:** Delivers accessible and high-quality healthcare solutions tailored to the unique healthcare landscapes of emerging markets.
- **India Business:** Features a diversified product portfolio across major therapy areas within India, including anti-tuberculosis, anti-diabetes, respiratory, and cardiology.
- **Specialty and Innovation:** Driven by science-led innovations, particularly in complex platforms such as inhalation and injectable technologies, to address unmet medical needs.
- **Biosimilars:** Aims to make complex biologics more accessible and affordable through in-depth research and quality-led manufacturing processes.
- **Our Adjacencies:** Engages in patient-centric initiatives that extend beyond medication to offer holistic healthcare support.

### Competitive strengths
- Global network of operations and personnel.
- Integrated manufacturing, procurement, and supply chain functions.
- Commitment to quality and compliance in all stages of operation.

## Related stocks

- [ABBOTINDIA (Healthcare)](https://faxioms.com/stocks/abbotindia) — +5.50%
- [ACUTAAS (Healthcare)](https://faxioms.com/stocks/acutaas) — +3.86%
- [AJANTPHARM (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +1.61%
- [ALKEM (Healthcare)](https://faxioms.com/stocks/alkem) — +0.14%
- [ANTHEM (Healthcare)](https://faxioms.com/stocks/anthem) — -0.35%

## Freshness and sources

- Data as of: 2026-09-18
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/lupin
Markdown representation: https://faxioms.com/stocks/lupin?render=md